New Trends in the Diagnosis and Therapy of Non-Alzheimer’s Dementia | ISBN 9783709168929

New Trends in the Diagnosis and Therapy of Non-Alzheimer’s Dementia

herausgegeben von Kurt A. Jellinger und Manfred Windisch
Mitwirkende
Herausgegeben vonKurt A. Jellinger
Herausgegeben vonManfred Windisch
Buchcover New Trends in the Diagnosis and Therapy of Non-Alzheimer’s Dementia  | EAN 9783709168929 | ISBN 3-7091-6892-9 | ISBN 978-3-7091-6892-9

New Trends in the Diagnosis and Therapy of Non-Alzheimer’s Dementia

herausgegeben von Kurt A. Jellinger und Manfred Windisch
Mitwirkende
Herausgegeben vonKurt A. Jellinger
Herausgegeben vonManfred Windisch

Inhaltsverzeichnis

Structural basis of dementia in neurodegenerative disorders.- Cytoskeletal pathology in non-Alzheimer degenerative dementia: new lesions in Diffuse Lewy body disease, Pick’s disease, and Corticobasal Degeneration.- The neuropathologic diagnostic criteria of frontal lobe dementia revisited. A study of ten consecutive cases.- Cognitive deficits in non-Alzheimer’s degenerative diseases.- The neurochemistry of Alzheimer type, vascular type and mixed type dementias compared.- Clinical features of frontal lobe dementia in comparison to Alzheimer’s disease.- Frontal lobe dementia and motor neuron disease.- Clinical and pathological characteristics of primary progressive aphasia and frontal dementia.- MR-imaging of non-Alzheimer’s dementia.- Functional imaging techniques in the diagnosis of non-Alzheimer dementias.- Quantitative EEG in frontal lobe dementia.- Vascular dementia: perfusional and metabolic disturbances and effects of therapy.- The spectrum of depressive pseudo-dementia.- Molecular biology of APO E alleles in Alzheimer’s and non-Alzheimer’s dementias.- Transmissible cerebral amyloidosis.- Human prion diseases.- The survival response of mesencephalic dopaminergic neurons to the neurotrophins BDNF and NT-4 requires priming with serum: comparison with members of the TGF-? superfamily and characterization of the serum-free culture system.- Tau protein and apolipoprotein E in CSF diagnostics of Alzheimer’s disease: impact on non-Alzheimer’s dementia?.- Death of cultured telencephalon neurons induced by glutamate is reduced by the peptide derivative Cerebrolysin®.- Molecular regulation of the blood-brain barrier GLUT1 glucose transporter by brain-derived peptides.- Cerebrolysin® protects neurons from ischemia-induced loss of microtubule — associatedprotein 2.- The long-term effect of NGF, b-FGF and Cerebrolysin® on the spatial memory after fimbria-fornix lesion in rats.- The influence of Cerebrolysin® and E021 on spatial navigation of young rats.- Effects of Cerebrolysin® on cytoskeletal proteins after focal ischemia in rats.- The short-term influence of b-FGF, NGF and Cerebrolysin® on the memory impaired after fimbria-fornix lesion.- Brain tissue hydrolysate, Cerebrolysin®, acts on presynaptic adenosine receptors in the rat hippocampus.